8-K: The Joint Corp. Reports 5% Revenue Growth in Q1 2024, Driven by Franchise Expansion

The Joint Corp. announced a 5% increase in revenue and a 9% increase in system-wide sales for the first quarter of 2024, alongside significant growth in franchise license sales.

Summary

• The Joint Corp. reported a 5% increase in revenue to $29.7 million for the first quarter of 2024, compared to $28.3 million in the same period last year.
• System-wide sales grew by 9% to $126.3 million, and system-wide comparable sales increased by 3%.
• The company achieved an operating income of $1.1 million, a significant improvement from an operating loss of $653,000 in Q1 2023.
• Net income was $947,000, compared to $2.3 million in the prior year, which included a $3.9 million employee retention credit.
• Adjusted EBITDA was $3.5 million, up from $2.0 million in the first quarter of 2023.
• The company sold 15 franchise licenses in Q1 2024, tripling the sales compared to Q4 2023.
• The total clinic count reached 954, with 23 new franchised clinics opened and 4 closed during the quarter.
• The company is actively pursuing a refranchising strategy for its corporate clinics, engaging an investment bank to assist in the process.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved profitability, and successful franchise expansion. The company's strategic initiatives and reiterated guidance contribute to a favorable sentiment, although some concerns about net income and potential risks exist.

Positives

• The company experienced a 5% increase in revenue year-over-year.
• System-wide sales saw a 9% increase, indicating strong performance across all clinics.
• Operating income improved significantly, moving from a loss to a profit of $1.1 million.
• Adjusted EBITDA increased by 72% year-over-year, demonstrating improved profitability.
• Franchise license sales tripled compared to the previous quarter, showing strong interest in the franchise model.
• The company opened 23 new franchised clinics, expanding its network.
• The company is actively working on refranchising its corporate clinics, which is expected to generate capital and increase franchise revenue.

Negatives

• Net income decreased to $947,000 from $2.3 million in Q1 2023, primarily due to the absence of a $3.9 million employee retention credit received in the prior year.
• System-wide comp sales for clinics open more than 48 months decreased by 3%.
• Loss on disposition or impairment increased to $362,000 from $65,000 in the first quarter of 2023, related to the refranchising efforts.

Risks

• The company faces challenges in recruiting and retaining qualified chiropractors and other personnel due to a nationwide labor shortage.
• Inflation has increased costs and could negatively impact the business.
• The company's refranchising efforts may not proceed as planned.
• Short-selling strategies and negative online opinions could negatively impact the stock price.
• The company may fail to remediate future material weaknesses in internal control over financial reporting.

Future Outlook

The company reiterated its 2024 guidance, expecting system-wide sales between $530 and $545 million, mid-single-digit system-wide comp sales, and 60 to 75 new franchised clinic openings, excluding the impact of refranchised clinics.

Management Comments

• Peter D. Holt, President and CEO, stated that the company began 2024 focused on increasing new patient counts, improving existing patient engagement, and refranchising the vast majority of their corporate portfolio.
• He also noted that the company is making solid progress on these goals.
• He mentioned that the strong interest in larger, more complex transactions led them to identify an investment bank specializing in refranchising.

Industry Context

The Joint Corp. operates in the chiropractic care industry, which is experiencing growth as people seek non-invasive and holistic pain management solutions. The company's focus on franchising and expanding its clinic network aligns with industry trends.

Comparison to Industry Standards

• The Joint Corp.'s 5% revenue growth and 9% system-wide sales growth in Q1 2024 are strong compared to the industry's 5-year CAGR of 5.1% as reported by Kentley Insights.
• The company's 58% CAGR in system-wide sales from 2010 to 2023 significantly outperforms the broader chiropractic market.
• While specific competitor data is not provided, The Joint Corp.'s focus on a retail healthcare model and franchise expansion differentiates it from traditional chiropractic practices.
• The company's refranchising strategy is a unique approach to optimizing its business model and is not a common practice among all chiropractic businesses.

Stakeholder Impact

• Shareholders will likely view the financial results and growth initiatives positively.
• Franchisees will benefit from the company's expansion and marketing efforts.
• Employees may be impacted by the company's efforts to address labor shortages.
• Customers will have increased access to chiropractic care through the expanding clinic network.

Next Steps

• The company will continue its refranchising efforts with the assistance of an investment bank.
• The company will focus on implementing new marketing programs to drive patient engagement.
• The company will continue to expand its clinic network through new franchise openings.

Key Dates

Keywords

chiropractic, franchise, revenue, system-wide sales, EBITDA, refranchising, clinic expansion, healthcare